Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…
Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025…
TOKYO, Oct. 16, 2025 /PRNewswire/ -- ESR, an Asia-Pacific ("APAC") focused real asset owner and manager, and Colt Data Centre…
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…
October 17, 2025 16:05 ET | Source: Jade Biosciences Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding…
With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top…
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world…
Integration of Origamis AI's enterprise GenAI orchestration platform, alongside the appointment of its co-founder to NuSummit's leadership, sharpens NuSummit's focus on secure, outcome-led AI at scale. MUMBAI, India, Oct. 15, 2025 /PRNewswire/ -- NuSummit, a…
Awards honor customers and partners who are redefining what's possible with data and AI BOSTON, Oct. 14, 2025 /PRNewswire/ --…